Toxins as biological weapons for terror—characteristics, challenges and medical countermeasures: a mini-review

Tamar Berger1,2, Arik Eisenkraft1,3,4, Erez Bar-Haim5, Michael Kassirer1, Adi Avniel Aran1,6 and Itay Fogel1*
usually more toxic than chemical agents, have a longer latency period, and are associated with a lower risk of environmental contamination [5, 6]. At the same time, there are several important differences between toxins and bio-terror pathogens: the morbidity and mortality rates are lower with toxins since they are not transmitted from person to person, and they will affect only those who were directly exposed to them following dispersion. This, together with their relatively short latency period compared to live pathogens, shortens the potential duration of the event. The non-contagious nature of toxins also reduces the need for neither healthcare surveillance nor using special protective gear by healthcare workers, apart from standard precautions. The need for environmental disinfection is minimized as the majority of toxins are sensitive to environmental conditions. Since there is no role for prophylactic treatment, there is no need in preparing large-scale points for dispensing drugs, as opposed to other live bio-terror agents [3, 6, 7].

Toxins cannot be grown in culture or identified by simple genetic sequencing of amino acids, making detection and treatment a more complex challenge. Furthermore, poisoning often presents with nonspecific clinical manifestations. Therefore, the primary diagnostic challenge in toxin exposure is to distinguish clusters of signs and symptoms from routine background morbidity. Toxins that are airborne tend to cause more severe illness than ingested toxins [8]. A high index of clinical suspicion is especially important in case of Botulinum neurotoxin poisoning; one of the few toxins for which there is an available anti-toxin and early administration is life-saving. In most cases, however, the only available treatment is supportive.

The aim of this work is to review the characteristics, diagnosis, and treatment of category A and B toxins, including Botulinum neurotoxin, staphylococcal enterotoxin B, Clostridium perfringens epsilon toxin, and ricin, in order to raise clinicians' awareness.

**Botulinum neurotoxin**

Botulinum neurotoxin (BoNT) is derived from the *Clostridium botulinum* bacterium and causes botulism. It is the most potent toxic substance currently known [9].

**Exploitation as a bio-weapon in the past**

BoNT was initially used as a biowarfare agent by the Japanese during World War II. Thereafter, it was produced by other countries as well, including the USA, USSR, and Iraq. In the 1990s, the Japanese cult Aum Shinrikyo attempted to launch several terror attacks with BoNT, but all of them failed [10, 11]. Given the ease of BoNT production, there is a risk of its future use for malicious purposes.

**Toxin source**

*Clostridium botulinum* is a gram-positive motile rod. There are seven serotypes of the bacterium (designated A–G) distinguished by the antigenic characteristics of the neurotoxins they produce. Serotypes A, B, E, and in rare cases, F have been described as causing disease in humans [9].

**Pathogenesis**

Natural BoNT poisoning usually occurs by ingestion of formed toxin as a result of inappropriate preparation and preservation of certain food items (food-borne botulism), or sometimes by spores germinating and producing the toxin in the immature intestinal tract of infants (infant botulism). Natural poisoning can also occur as a consequence of bacterial overgrowth in necrotic wounds (wound botulism) or in individuals with a gastrointestinal disease (adult colonization botulism). Inhalational exposure to BoNT aerosol is regarded as a possible bio-terror threat. In any case, the disease develops within 12–36 h from the moment the toxin enters the body, regardless of the route of exposure [9, 12].

**Mechanism of action and resistance**

BoNT is active in the neuromuscular junctions of the peripheral nervous system. It acts by blocking acetylcholine release from the presynaptic nerve endings, causing weakness and paralysis of the corresponding muscles. The interference with synaptic activity is prolonged owing to the long half-life of the toxin [10]. The toxin can be inactivated in a temperature of 85 °C for a period of 5 min, by exposure to the sun for 1–3 h, or by using chlorine solutions [13].

**Clinical manifestations**

All forms of botulism lead to the same clinical syndrome of symmetrical cranial neuropathy, including diplopia, ptosis, dysphagia, xerostomia, dysphonia, or dysphasia, in combination with symmetrical descending paralysis. In most cases, there is no fever. Occasionally, gastrointestinal symptoms, such as abdominal pain, nausea, vomiting, or diarrhea, may precede the neurological presentation. The paralysis may progress to include the respiratory muscles with subsequent respiratory failure [9, 12].

**Diagnosis**

The clinical diagnosis of botulism is based mainly on medical history and physical examination. In naturally-occurring botulism, the bacteria can be isolated from stool, blood, or food samples. In a bio-terror scenario, when individuals are exposed to an aerosolized toxin, traditional microbiological tests are not helpful. Gene detection methods are an option if the offending substance
contains bacterial residue. The gold-standard diagnostic test is the indirect mouse neutralization bioassay (see Ref. [14] for details). The main disadvantage of this test is its 96-h duration and lack of sufficient sensitivity. A new method of endopeptidase-mass spectrometry is gaining credibility as a promising method that addresses the limitations of the mouse assay [15–19]. Electromyography can strongly support the clinical diagnosis showing a typical pattern for botulism. Findings on routine blood tests and brain imaging are usually normal, but may serve to rule out other diagnoses [9, 12, 13].

**Treatment**

Treatment of botulism is mainly supportive, including prolonged mechanical ventilation. An equine-derived anti-toxin has been produced which inhibits the free toxin from binding to nerve endings, thereby preventing paralysis and respiratory insufficiency. Its efficacy diminishes once clinical signs develop, thus treatment should be administered immediately on grounds of clinical suspicion, prior to definite laboratory diagnosis. The anti-toxin is administered only in a hospital setting because of the risk of anaphylactic reaction. However, with the recent introduction of a product consisting only of the F(ab)2 segment of the antibody, anaphylaxis has become rare [12, 13, 20].

**Prevention**

In the past, an active vaccine containing formalin-treated toxin was administered to laboratory personnel at risk of coming into contact with the toxin. The CDC has since discontinued this practice [21].

**Staphylococcal enterotoxin B**

Staphylococcal enterotoxin B (SEB) is produced by the *Staphylococcus aureus* bacterium [22]. It is the only toxin of *S. aureus* that is classified as a bio-terror agent.

**Exploitation as a bio-terror agent**

Inhalational exposure to SEB is extremely rare, and any event should immediately raise suspicions of malicious intent [23]. A series of laboratory accidents in the 1940s–1960s in the United States led to intensive research of the toxin which yielded a vast amount of pertinent information [24].

**Toxin source**

*Staphylococcus aureus* is a gram-positive bacterium which does not produce spores and can survive in both aerobic and anaerobic conditions. It exists in nature on the skin and mucosa of humans and animals and can be found among the normal respiratory tract flora of 25–50 % of the population [25–27].

**Pathogenesis**

SEB poisoning occurs mainly by consumption of contaminated food or water, and is considered a bioterror threat mainly due to the potential for an intentional use in food poisoning scenarios. Other routes of entry are the respiratory tract, the vaginal tract (via infection of a vaginal tampon, leading to the "toxic shock syndrome"), and the eyes (causing conjunctivitis). SEB is toxic in relatively minute doses [28]. It is not transmitted from person to person by contact or through air [22].

**Mechanism of action and resistance**

SEB has several advantages as a bio-warfare agent, including its solubility in water, relatively high resistance to heat (it remains active even after a few minutes in boiling water) and to acidic pH levels and it is easily dispersed in air. The protein has a unique structure to sustain intestinal proteases [22, 25–27, 29]. The mechanism by which it exerts its intestinal injury is not fully clear. In the case of toxic shock syndrome it brings to a non-specific activation of T cell lymphocytes, bypassing the specific interaction between T-cell receptors and major histocompatibility complex molecules, which results in a cytokine storm [22, 27, 30].

**Clinical manifestations**

The symptoms of SEB poisoning depend on the route of exposure. The toxin is most dangerous when inhaled, causing hyperpyrexia within 3–12 h of exposure in addition to cough, rigor, headache, and myalgia. The fever may last for 2–5 days, and the cough up to 4 weeks. Inhalation of high doses may lead to acute respiratory distress syndrome (ARDS), and trigger shock and multi-organ failure [22–24, 26, 31–33]. Ingestion of SEB leads to nausea, vomiting, diarrhea, and abdominal cramps, which appear within 1–8 h of exposure, without fever or respiratory symptoms. Symptoms usually resolve within 24–48 h [22, 24, 25, 27, 31–34].

**Diagnosis**

SEB can be detected by immunological assays in blood, urine, or sputum [35] up to 12–24 h from exposure; after that, it is undetectable in body fluids [24, 27]. In solid or liquid food products, SEB is detectable even in minute concentrations. Occasionally, polymerase chain reaction (PCR) is useful for detecting residual bacterial DNA in water, food, or clinical samples. Serology is usually beneficial only for retrospective detection of the toxin [36, 37].

**Treatment and prevention**

Treatment is mainly supportive and does not require antibiotics. Currently, there is no available antidote or preventive vaccine, although there are several ongoing
attempts at vaccine development, still in preliminary stages [34, 38–40].

**Clostridium perfringens epsilon toxin**
The Clostridium perfringens Epsilon toxin (ETX) is the third most potent toxin in nature following BoNT and the tetanus toxins [31, 41]. The toxin is produced by the gram-positive, rod-shaped spore-forming anaerobic bacterium Clostridium perfringens type B and D, and impacts usually ruminants, especially young sheep, where it can cause a highly lethal enterotoxemia [41, 42].

**Exploitation as a bio-terror agent**
The existing literature does not suggest that human poisoning by ETX naturally occurs even infrequently [43]. ETX is considered as a potential bioterrorism agent due to its high potency, and has been classified as a category B agent by the CDC [31, 41, 44]. Possible exposure route in case of a bioterror attack include aerosol, and food-and waterborne exposures [45].

**Toxin source**
The natural habitat of the toxin-producing bacterium is the environment, and it can be found in soil, dust, sediment, litter, cadavers, and even in the digestive tract of healthy animals though in low numbers [42]. Only few ETX-mediated natural diseases have been reported in man [31, 42].

**Pathogenesis**
Following rapid growth of the bacterium, such as in the intestines of young animals in which the resident digestive tract microflora is not yet developed or functional, or in cases of overeating a rich diet high in cereal crops leading to a passage of undigested fermentable carbohydrates, high production of ETX may occur, followed by enterotoxemia and injury to other target organs [42].

**Mechanism of action and resistance**
ETX is produced in the exponential growth phase of the bacterium as a prototoxin. It is then converted by specific proteases to an active ETX in the intestines [41, 46]. ETX is a pore-forming toxin that increases cell permeability to small molecules and ions [31, 41]. The toxin acts locally in the intestines, increases the permeability of the gut mucosa, and then passes through and disseminates through the circulation to other organs, causing microvascular endothelial lesions mainly in the brain, the lungs and the kidneys, leading to toxic shock and death [41, 42, 46, 47]. In the kidneys it will cause interstitial hemorrhage with edema and degeneration of tubular epithelium [42, 44]. In the brain it alters the integrity of the blood–brain-barrier, causing bilateral symmetrical lesions in several brain areas consisting of perivascular edema [42, 48], resulting in foci of hemorrhage and necrosis and leading to neuronal damage [41, 42, 49]. ETX also has a direct and rapid effect in brain through targeting specific glutamatergic neurons, stimulating glutamate release and inducing neuronal cell damage [50, 51]. Once aerosolized, the toxin is stable in environmental conditions for a period of 8 h, and exposure to even a minute dose of 1 µg/kg may be fatal [45].

**Clinical manifestations**
There are no available reports examining the effects of ETX on humans besides two case reports in humans published in the 1950s [31, 41]. However, it is evident that the toxin imposes risk to humans, either in natural conditions or in a bioterror setting through mass dissemination via aerosol [41, 44]. In the lack of reliable or established human data, it is assumed that there is a latent period lasting for 1–12 h between exposure and the appearance of clinical signs and symptoms. Inhalation of the toxin may result in vascular endothelial cell damage in the lungs, leading to pulmonary edema. From the lungs, the toxin will be spread to other organs, with renal, cardiovascular and central nervous system injuries, resulting in brain edema, altered consciousness, seizures, and within several hours, death will ensue [41, 44, 45].

**Diagnosis**
Since introducing non-animal alternatives, the classic mouse assay involving toxin neutralization with *C. perfringens* type-specific antiserum is less in use. Use of ELISA technology for specifically detecting ETX in intestinal contents is one of the best ways to confirm poisoning [52]. Quantitation of ETX protein is also possible using a novel, mass spectrometry technique [43, 53]. Mass spectrometry avoids cross-reactivity issues intrinsic in any antibody-based assay; however, ELISA and mass spectrometry do not determine whether the detected protein is biologically active. A latex agglutination test has been developed and a cytotoxicity assay using Madin–Darby canine kidney (MDCK) cells has been published [54]. PCR assays can identify the epsilon toxin gene, if it is present [43]. In the first stages of the disease, laboratory tests may show hemolytic anemia, thrombocytopenia, hypoxemia, and elevated liver enzymes. In later stages, pancytopenia is evident [45].

**Treatment and prevention**
The mainstay of medical treatment is supportive care. Currently, there is a formalin-inactivated vaccine and an equine-derived antitoxin approved for animal use only. The high lethality and the rapid onset of clinical manifestations limit their efficacy [41, 55, 56]. Specific
high-affinity toxin antagonists being investigated include monoclonal antibodies and selected oligonucleotides (aptamers) and dendrimer-based polymers [41, 42, 57]. Caregivers should use standard precaution measures when treating ETX casualties.

**Ricin**
Ricin is produced from the *Ricinus communis* plant which is found worldwide.

**Exploitation as a bio-terror agent**
Ricin was investigated as a bio-warfare agent in the 1940s in the USA and was used in the assassination of the Bulgarian journalist Georgi Markov in 1978. Ricin may also have been used in the Iran-Iraq war in the 1980s. Recently, envelopes containing ricin powder were sent by terror organizations to government personnel in Great Britain and in the USA [58–60].

**Pathogenesis**
Ricin can be produced in liquid or solid forms (as a powder). It can be injected or disseminated via food, water, or air [61, 62]. All routes of exposure except ingestion are usually intentional, but human-to-human transmission does not occur [60]. Ricin is highly toxic, especially when inhaled, but it is considered less potent than other toxins [5, 59].

**Mechanism of action and resistance**
Ricin penetrates the cells by binding to cell membrane receptors. It acts by inhibiting protein synthesis at the level of the ribosome [6]. Ricin is stable in environmental conditions. It can be inactivated at a temperature of 80 °C for a period of 10 min or at 50 °C for a period of 1 h, and by using chlorine solutions [5].

**Clinical manifestations**
The clinical presentation of ricin poisoning depends on the dosage and route of exposure. Symptoms of inhalational exposure appear within 4–8 h and are nonspecific, including fever, cough, dyspnea, nausea, diaphoresis, and arthralgia. Studies in animals exposed to inhalational ricin reported such pathophysiological changes as necrosis and pulmonary edema leading to death from ARDS and respiratory failure within 36–72 h [63]. Respiratory symptoms do not occur in other routes of exposure, although pulmonary edema may develop due to capillary leak syndrome.

Intramuscular injection of ricin leads to local muscle necrosis and regional lymphadenopathy with minimal involvement of internal organs. Following ingestion of ricin, the clinical manifestations include: nausea and vomiting, diarrhea, hypotension, hematuria, and renal failure. Further tests reveal necrosis of intestinal epithelial cells, hemorrhage, and necrosis of the liver, spleen and kidneys. Some patients have hallucinations, seizures, and life-threatening multi-organ failure. Findings on blood and urine analysis are nonspecific: elevated levels of transaminases, lactate dehydrogenase and bilirubin, leukocytosis, metabolic acidosis, hypoglycemia or hyperglycemia, increased creatine kinase, and proteinuria. There may also be electrocardiogram changes.

Exposure to ricin via direct contact of skin or mucous membranes is not typical and may lead to erythema and pain [5, 59–61].

**Diagnosis**
Clinical suspicion of inhalational exposure to ricin is based on the appearance of severe respiratory illness in a cluster of otherwise healthy individuals with a common epidemiological background. The diagnosis is made by immunoassays of clinical samples taken from nasal mucosa, skin or blood, or environmental samples taken from the point of dispersion. Serology is useful only for retrospective documentation. Occasionally, *Ricinus communis* plant DNA can be detected in products containing ricin [59, 60]. Urine can be tested for ricinine level within 2 days after exposure, since ricinine and ricin originate from the same source [62]. Studies have recently suggested the use of nanopores covered with short single-stranded DNA or RNA molecules, called aptamers, which bind to pre-selected targets with high affinity and specificity [64]. This novel method has shown high potential as both a diagnostic and a therapeutic tool [64].

**Treatment**
Even before referral to the hospital, patients exposed to ricin powder should be immediately undressed and washed with soap and water. In the event of blurred vision or direct contact with the eyes, the eyes should be rinsed with water [60]. In-hospital treatment consists of rehydration, restoration to normal electrolyte levels, and respiratory support if needed. Gastric lavage or activated charcoal have not proven effective but can be used in the first hour after oral poisoning [59, 61]. Dialysis is not effective. Specific anti-toxin is currently in advanced developmental stages [59, 61].

**Prevention**
Active vaccinations based on toxoid or mutant toxin are being developed. One of these is RiVax, based on a derivative of the toxin's subunit-A chain that is enzymatically inactive and lacks the residual toxicity of the holotoxin. Animal models show it has a high efficacy and a good safety profile in humans [59, 61, 65].
Conclusions

Toxins are a unique subgroup of bio-threat pathogens. BoNT, SEB, ETX, and ricin are considered by the CDC to be potential bioterror agents owing to their short incubation period and high toxicity. This review highlights important characteristics of these toxins in this context, as distinct from living pathogens and chemical warfare agents. These differences require different means of preparedness, diagnosis, treatment, containment, and prevention. A finding of a cluster of previously healthy individuals with severe respiratory symptoms in the absence of a known causative agent and in the appropriate epidemiological setting should raise clinical suspicions of exposure to a toxin. Clinicians need to be familiar with the unique features of toxins and their clinical manifestations in order to administer supportive care or specific treatments as soon as possible to prevent clinical deterioration and contain outbreaks.

Abbreviations

CDC: Centers for Disease Control and Prevention; BoNT: Botulinum neurotoxin; SEB: staphylococcal enterotoxin B; ARDS: acute respiratory distress syndrome; ETX: epsilon toxin; MDCK: Madin–Darby canine kidney.

Authors’ contributions
TB drafted the section of the BoNT. AE drafted the section of the epsilon toxin and critically revised the manuscript. EB drafted the section of ricin and revised the BoNT and SEB drafts. MK drafted the introduction section. AAA also drafted the introduction and revised the manuscript. IF drafted the sections of the SEB and epsilon toxin and critically revised the manuscript. All authors read and approved the final manuscript.

Author details
1. Surgeon General Headquarters, IDF Medical Corps, Tel Hashomer, Israel.
2. Department of Internal Medicine, Rabin Medical Center, Petah Tikva, Israel.
3. Institute for Research in Military Medicine, Faculty of Medicine, The Hebrew University, Jerusalem, Israel.
4. NBC Protection Division, IMOD, Tel Aviv, Israel.
5. Department of Biochemistry and Molecular Genetics, Israel Institute for Biological Research, Ness Ziona, Israel.
6. Pediatric Critical Care Unit, Children’s Hospital, Montefiore Medical Center, Bronx, NY, USA.

Competing interests
The authors declare that they have no competing interests.

Received: 18 November 2015 Accepted: 23 April 2016
Published online: 29 April 2016

References

1. Busl KM, Bleck TP. Treatment of neuroterrorism. Neurotherapeutics. 2012;9(1):139–57.
2. Vatansever F, Ferraresi C, de Sousa MV, Yin R, Rineh A, Sharma SK, Hamblin MR. Can biowarfare agents be defeated with light? Virulence. 2013;4(8):796–825.
3. Clarke SC. Bacteria as potential tools in bioterrorism, with an emphasis on bacterial toxins. Br J Biomed Sci. 2005;62(1):40–6.
4. Bioterrorism overview. Centers for Disease Control and Prevention website. Updated February 12, 2007. http://emergency.cdc.gov/bioterrorism/
5. Darling RG, Woods JB. Medical management of biological casualties handbook. 5th ed. Fort Detrick, MD: US Army Medical Research Institute of Infectious Diseases; 2004. p. 80–91 (appendix I).
6. Madsen JM. Toxins as weapons of mass destruction. A comparison and contrast with biological-warfare and chemical-warfare agents. Clin Lab Med. 2001;21:593–605.
7. Marks JD. Medical aspects of biologic toxins. Anesthesiol Clin North Am. 2004;22:509–32, vii.
8. Yinon A. Introduction to toxins. In: Brener B, Catz L, Rubinstein A, et al., editors. The biology book: medical aspects and responses [Hebrew]. Netanya: SAREL Logistics Solutions & Products for Advanced Medicine; 2002. p. 109–12.
9. Centers for Disease Control and Prevention. Botulism: information and guidance for clinicians. Updated June 14, 2006. http://www.bt.cdc.gov/agent/botulism clinicians. Accessed 2 Jan 2016.
10. Keller JE, Neale EA, Oyler G, Adler M. Persistence of botulinum neurotoxin action in cultured spinal cord cells. FEMS Lett. 1999;456:137–42.
11. Dembek ZF, Smith LA, Rusnak JM. Botulinum toxin. In: Dembek ZF, editor. Medical aspects of biological warfare. Washington, DC: Office of the Surgeon General, US Army Medical Department Center and School; Borden Institute, Walter Reed Army Medical Center; 2007. p. 337–53.
12. State of Israel, Ministry of Health. The Israelis doctrine for botulism [Hebrew]. Updated May, 2011. http://www.health.gov.il/Subjects/emergency/preparation/DocLib/1ora/BIO_TORA_BOTULISM.pdf. Accessed 2 Jan 2016.
13. Villar R, Elliott S, Davenport K. Botulism: the many faces of botulinum toxin and its potential for bioterrorism. Infect Dis Clin North Am. 2006;20:313–27.
14. Centers for Disease Control and Prevention. Botulism in the United States (1899–1996). Handbook for epidemiologists, clinicians, and laboratory workers. Atlanta, GA: US Department of Health, Education, and Welfare, CDC, 1998.
15. Barr JR, Moura H, Boyer AE, et al. Botulinum neurotoxin detection and differentiation by mass spectrometry. Emerg Infect Dis. 2005;11(10):1578–83.
16. Boyer AE, Moura H, Woolfitt AR, et al. From the mouse to the mass spectrometer: detection and differentiation of the endoproteinase activities of botulinum neurotoxins A–G by mass spectrometry. Anal Chem. 2005;77(13):3916–24.
17. Rosen Q, Feldberg L, Gura S, Zichel R. Improved detection of botulinum type E by rational design of a new peptide substrate for endopeptidase-mass spectrometry assay. Anal Biochem. 2014;456:50–2.
18. Rosen Q, Feldberg L, Gura S, Zichel R. A new peptide substrate for enhanced BoNT/B detection by endopep-LC-MS/MS/MMR assay. Anal Biochem. 2015;473:7–10.
19. Rosen Q, Feldberg L, Gura S, et al. Early, real-time medical diagnosis of botulism by endopeptidase-mass spectrometry. Clin Infect Dis. 2015;61(12):e58–61.
20. Arnon SS, Schechter R, Ingleby TV, Working Group on Civilian Biodefense, et al. Botulism toxin as a biological weapon: medical and public health management. JAMA. 2001;285:1059–70.
21. Centers for Disease Control and Prevention (CDC). Notice of CDC’s discontinuation of investigational pentavalent (ABCDE) botulinum toxoid vaccine for workers at risk for occupational exposure to botulinum toxins. MMWR Morb Mortal Wkly Rep. 2011;60:1454–5.
22. Pinchuk IV, Beswick EJ, Reyes VE. Staphylococcal enterotoxins. Toxins. 2010;2:2177–97.
23. Rajagopalan G, Sen MM, Singh M, et al. Intranasal exposure to staphylococcal enterotoxin B elicits acute systemic inflammatory response. Shock. 2006;25:647–56.
24. Rusnak JM, Kortepeter M, Utcht R, Poll M, Boudreau E. Laboratory exposures to staphylococcal enterotoxin B. Emerg Infect Dis. 2004;10:1544–9.
25. McKay DM. Bacterial superantigens: provocateurs of gut dysfunction and inflammation? Trends Immunol. 2001;22:497–501.
26. Foster TJ. Immune evasion by staphylococci. Nat Rev Microbiol. 2005;3:948–58.
27. Fraser JD, Proft T. The bacterial superantigen and superantigen-like proteins. Immunol Rev. 2008;225:226–43.
28. Gill DM. Bacterial toxins: a table of lethal amounts. Microbiol Rev. 1982;46:86–94.
29. Pappagianis DB, Acharya KR. Microbial superantigens: from structure to function. Trends Microbiol. 2000;8:69–75.
30. Kappler J, Kotzin B, Herron L, et al. V beta-specific stimulation of human T cells by staphylococcal toxins. Science. 1989;244:811–3.
31. Manis NJ. Vaccines against the category B toxins: staphylococcal enterotoxin B, epsilon toxin and ricin. Adv Drug Deliv Rev. 2005;57:1424–39.
32. Ohlsen K, Lorenz U. Immunotherapeutic strategies to combat staphylococcal infections. Int J Med Microbiol. 2010;300:402–10.
33. Kumar S, Ménoret A, Ngoi SM, Vella AT. The systemic and pulmonary immune response to staphylococcal enterotoxins. Toxins (Basel). 2010;2:1898–912.
34. Musch MW, Petrof EO, Kojima K, Ren H, McKay DM, Chang EB. Bacterial superantigen-treated intestinal epithelial cells upregulate heat shock proteins 25 and 72 and are resistant to oxidant cytotoxicity. Infect Immun. 2004;72:3187–94.
35. Cook E, Wang X, Robson N, Fries BC. Measurement of staphylococcal enterotoxin B in serum and culture supernatant with a capture enzyme-linked immunosorbent assay. Clin Vaccine Immunol. 2007;14:1094–101.
36. Soto CM, Martin BD, Sapsford KE, Blum AS, Ratna BR. Toward single molecule detection of staphylococcal enterotoxin B mobile sandwich immunoassay on gliding microtubes. Anal Chem. 2008;80:9433–40.
37. Yang M, Kostov Y, Bruck HA, Rasooly A. Gold nanoparticle-based enhanced chemiluminescence immunosensor for detection of staphylococcal enterotoxin B (SEB) in food. Int J Food Microbiol. 2009;133:265–71.
38. Woody MA, Krakauer T, Stiles BG. Staphylococcal enterotoxin B mutants (N23 K and F44S): biological effects and vaccine potential in a mouse model. Vaccine. 1997;15:133–9.
39. Krakauer T. Chemotherapeutics targeting immune activation by staphylococcal superantigens. Med Sci Monit. 2005;11:290–5.
40. Yang X, Buonpane RA, Moza B, et al. Neutralization of multiple staphylococcal superantigens by a single-chain protein consisting of affinity-matured, variable domain repeats. J Infect Dis. 2008;198:344–8.
41. Alves GG, Machado de Ávila RA, Chávez-Olórtegui CD, Lobato FC. Clostridium perfringens epsilon-toxin increases permeability of single perfused microvessels of rat mesentery. Infect Immun. 2006;74:7116–21.
42. Poli MA, Roy C, Huebner KD, et al. Ricin. In: Dembek ZF, editor. Medical aspects of biological warfare. Washington, DC: Office of the Surgeon General. 2007. p. 323–35.
43. O’Hara JM, Brey RN III, Mantis NJ. Comparative efficacy of two leading candidate ricin toxin a subunit vaccines in mice. Clin Vaccine Immunol. 2013;20:789–94.
44. Finnie JW. Pathogenesis of brain damage produced in sheep by Clostridium perfringens type epsilon toxin. Toxins (Basel). 2011;3:219–21.
45. Finnie JW, Manavis J, Blumbergs PC. Aquaporin-4 in acute cerebral edema produced by Clostridium perfringens type epsilon toxin. Vet Pathol. 2008;45(3):307–9.
46. Miyamoto O, Minami J, Toyoshima T, et al. Neurotoxicity of Clostridium perfringens epsilon-toxin for the rat hippocampus via the glutamatergic system. Infect Immun. 1998;66(6):2501–8.
47. Miyamoto O, Sumitani K, Nakamura T, et al. Clostridium perfringens epsilon toxin causes excessive release of glutamate in the mouse hippocampus. FEMS Microbiol Lett. 2000;189(1):109–13.
48. Layana JE, Fernandez-Miyakawa ME, Uzal FA. Evaluation of different fluids for detection of Clostridium perfringens type D epsilon toxin in sheep with experimental enterotoxicemia. Anaerobe. 2006;12:204–6.
49. Seyer A, Fenaillé F, Feraudet-Tarisse C, et al. Rapid quantification of clostridial epsilon toxin in complex food and biological matrices by immunopurification and ultraformance liquid chromatography-tandem mass spectrometry. Anal Chem. 2012;84(10):5103–9.
50. Payne DW, Williamson ED, Havard H, Modi N, Brown J. Evaluation of a new cytotoxicity assay for Clostridium perfringens type D epsilon toxin. FEMS Microbiol Lett. 1994;116:161–8.
51. McClain MS, Cover TL. Functional analysis of neutralizing antibodies against Clostridium perfringens epsilon toxin. Infect Immun. 2007;75(4):1785–93.
52. Titball RW. Clostridium perfringens vaccines. Vaccine. 2009;27(Suppl 1):D144–7.
53. Paddle BM. Therapy and prophylaxis of inhaled biological toxins. J Appl Toxicol. 2003;23(3):139–70.
54. Mayor S. UK doctors warned after ricin poison found in police raid. BMJ. 2003;326(7381):1316.
55. Poli MA, Roy C, Huebner KD, et al. Ricin. In: Dembek ZF, editor. Medical aspects of biological warfare. Washington, DC: Office of the Surgeon General. 2007. p. 323–35.
56. Centers for Disease Control and Prevention. Facts about ricin. Updated May 9, 2013. http://emergency.cdc.gov/agent/ricin/facts.asp. Accessed 2 Jan 2016.
57. Bradberry SM, Dickens KJ, Rice P, Griffiths GD, Vale JA. Ricin poisoning. Toxicol Rev. 2003;22:65–70.
58. Moran-Glad, I, Tusk-Heleman, L, Fogel I, et al. Ricin and abrin as potential bio-terror agents [Hebrew]. J Isr Millitry Med. 2010;7:124–6.
59. Greenfield RA, Brown BR, Hutchins JB, et al. Microbiological, biological, and chemical weapons of warfare and terrorism. Am J Med Sci. 2002;323:326–40.
60. Gu LQ, Ding S, Gao C. Aptamer-encoded nanopore for ultrasensitive detection of bioterrorist agent ricin at single-molecule resolution. In: Conf Proc IEEE Eng Med Biol Soc. 2009; 90:6699–702.